Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

11.60 +1.77 (+17.96%)
Streaming Delayed Price Updated: 1:18 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,281,908
Open 10.15
Bid (Size) 11.59 (600)
Ask (Size) 11.60 (300)
Prev. Close 9.830
Today's Range 9.950 - 11.71
52wk Range 1.830 - 11.00
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗
ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types. 
Via Stocktwits
News headline image
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion. 
Via The Motley Fool
Topics Stocks

Performance

YTD
+474.0%
+474.0%
1 Month
+86.7%
+86.7%
3 Month
+439.3%
+439.3%
6 Month
+415.3%
+415.3%
1 Year
+260.1%
+260.1%

More News

Read More
News headline image
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
From ImmunityBio, Inc.
Via Business Wire
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Again Today ↗
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
Via Stocktwits
News headline image
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough ↗
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
Via Stocktwits
News headline image
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Economy Government
News headline image
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗
Via Stocktwits
Topics Government
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
Via Finterra
Topics Lawsuit
News headline image
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
Via Stocktwits
News headline image
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Economy Government
News headline image
Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗
Via Stocktwits
News headline image
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗
Via The Motley Fool
Topics Initial Public Offering Stocks
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Today ↗
Via The Motley Fool
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 11.60
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 02/24/26 01:18 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 4.54B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.